前列腺素E1治疗慢性病毒性肝炎、肝硬化及重症肝炎的疗效

Clinical observation on the effects of prostaglandin El in patients with chronic viral hepatitis, hepatic cirrhosis and severe hepatitis

目的:进一步探讨前列腺素El(PGEl)对病毒性肝炎的疗效.方法:对95例慢性乙型肝炎、肝炎肝硬化及重症肝炎在综合护肝治疗的基础上加用PGEl治疗,疗程14～21d,另设对照组90例.结果:PGEl治疗组中血清总胆红素(SB)的降低明显优于对照组(P<0.05),在慢性肝炎病例组中,治疗组中ALT的下降显著低于对照组(P<0.05);而在重症肝炎组中.虽然两组的病死率无显著性差异.但治疗组中[凝血]因子Ⅱ活动度(PTA)及病情好转率均明显优于对照组(P<0.05).结论:PGEl对慢性肝炎、肝硬化及重症肝炎有一定疗效.

AIM: To study the effects of prostaglandin El (PGE1) on viral hepatitis. METHODS: Ninety-five patients of chronic hepatitis B, hepatic cirrhosis and severe hepatitis were treated with PGEl for 14~20 d. 90 cases were given a general liver protective therapy as control. RESULTS: The total serum bilirubin (SB) in the group of cases who were treated with PGEl was significantly lower than that of the control group (P<0. 05). The ALT of the chronic hepatitis cases in the former group was significantly lower than that of the latter group (P<0. 05). Although the fatality rates were not found significantly differences between 2 groups of cases of severe hepatitis, the FTA and recovery rates in the group of PGEl treatment were significantly higher than that of the group of control (P<0. 05). CONCLUSION: PGEl is effective to decline SB and ALT in chronic hepatitis, hepatic- 211 -cirrhosis and severe hepatitis, and it is helpful for the recovery of severe hepatitis.